title: Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.
authors.forename: Katja
authors.initials: K
authors.lastname: Sockel
authors.forename: Martin
authors.initials: M
authors.lastname: Bornhaeuser
authors.forename: Eva
authors.initials: E
authors.lastname: Mischak-Weissinger
authors.forename: Rudolf
authors.initials: R
authors.lastname: Trenschel
authors.forename: Martin
authors.initials: M
authors.lastname: Wermke
authors.forename: Christian
authors.initials: C
authors.lastname: Unzicker
authors.forename: Guido
authors.initials: G
authors.lastname: Kobbe
authors.forename: Jürgen
authors.initials: J
authors.lastname: Finke
authors.forename: Ulrich
authors.initials: U
authors.lastname: Germing
authors.forename: Brigitte
authors.initials: B
authors.lastname: Mohr
authors.forename: Jochen
authors.initials: J
authors.lastname: Greiner
authors.forename: Dietrich
authors.initials: D
authors.lastname: Beelen
authors.forename: Christian
authors.initials: C
authors.lastname: Thiede
authors.forename: Gerhard
authors.initials: G
authors.lastname: Ehninger
authors.forename: Uwe
authors.initials: U
authors.lastname: Platzbecker
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002869:Chromosome Aberrations; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D013792:Thalidomide / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide